about
VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyRecent advances in treating Parkinson's disease.mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal CortexThe Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related DisordersCurrent Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.Promising therapeutic agents for the treatment of Parkinson's disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5.Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.
P2860
Q30366876-8B267562-E56D-4B03-934B-7C66AB9EBC3DQ34554401-FE7DE51B-258A-48AF-B7CC-6F1D3A60036AQ35867117-7EDC8A83-5EC8-43DD-BF9A-BB1F6C71DD6EQ37172873-D90E5DC8-23DC-4350-B682-F7F9E45BB4B9Q38658203-93177F60-573E-44C4-9B56-A8F98B1B9538Q38690069-F94CA659-1BB6-441E-844C-12CC175F365BQ38767711-84F19AC9-7A5F-4B7D-8D0B-03DF6B6E43A8Q38845546-A1D98E58-B7C2-48BD-9D65-E7524A3C5049Q39008496-267B0DA0-D97D-4401-88AE-BE70D4EDBD3CQ39076410-A94316F0-3A42-4E99-A9E9-7D5E5A884713Q39325939-2080C3F9-C16D-428E-B2CC-991DAF77785FQ48077200-1D5883D3-2E45-4ECD-B448-ECAF502F456FQ52600080-BFC1317D-D182-4EE1-A0CA-B1D4D02522B8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mavoglurant as a treatment for Parkinson's disease.
@en
type
label
Mavoglurant as a treatment for Parkinson's disease.
@en
prefLabel
Mavoglurant as a treatment for Parkinson's disease.
@en
P2093
P2860
P50
P1476
Mavoglurant as a treatment for Parkinson's disease
@en
P2093
Anna Maria Canudas
Carlos Beas-Zarate
Carme Auladell
Dmitry Petrov
Ignacio Pedros
Maria Luisa de Lemos
P2860
P304
P356
10.1517/13543784.2014.931370
P407
P577
2014-06-24T00:00:00Z